Literature DB >> 3841303

Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids.

B A Holm, R H Notter, J N Finkelstein.   

Abstract

These experiments characterize the effects of albumin on the dynamic surface activity of natural lung surfactant (LS), and an extracted mixed lipid fraction (CLL), at physiologic temperature, humidity, and film cycling rate on an oscillating bubble apparatus. Measurements of albumin effects on the surface pressure-time (pi-t) adsorption isotherms of CLL and LS are also reported. Results show that albumin in concentrations greater than or equal to 20 mg/ml increased the minimum dynamic surface tension of LS suspensions (0.4 mg phospholipid/ml) from less than 1 dyne/cm to 21 dynes/cm at 37 degrees C. Albumin in low concentrations (2 mg/ml) had a similar detrimental effect on the dynamic surface activity of extracted surfactant lipids, CLL. In addition, albumin also inhibited the isolated adsorption facility of LS and CLL; instead of adsorbing rapidly to their maximum spreading pressures of 45 dynes/cm, both surfactant mixtures (at 0.063 and 0.125 mg phospholipid/ml) adsorbed more slowly or reached lower final surface pressures in the presence of plasma protein. A striking finding was that albumin inhibition of surface activity was moderated or abolished at high lipid concentrations. For example, minimum dynamic surface tensions less than 1 dyne/cm were reached on the oscillating bubble for natural LS at concentrations greater than 0.75 mg/ml and CLL at concentrations greater than 1.5 mg/ml, even in the presence of very large amounts of albumin (100 mg/ml). Similarly, LS and CLL adsorption facility was protected from albumin inhibition at sufficiently high phospholipid concentrations. Albumin inhibition of natural LS adsorption was also moderated by the presence of 1.4 mM Ca2+ ions. These results show that albumin in plasma transudates has the potential to seriously impair alveolar surfactant activity in vivo. However, the detrimental effect will be mitigated if a critical threshold of phospholipid is present.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841303     DOI: 10.1016/0009-3084(85)90022-2

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  38 in total

1.  A concentration-dependent mechanism by which serum albumin inactivates replacement lung surfactants.

Authors:  H E Warriner; J Ding; A J Waring; J A Zasadzinski
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

Review 2.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.

Authors:  M Gupta; J M Hernandez-Juviel; A J Waring; F J Walther
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 4.  Surfactant therapy for meconium aspiration syndrome: current status.

Authors:  Peter A Dargaville; John F Mills
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental.

Authors:  H William Taeusch; Jorge Bernardino de la Serna; Jesus Perez-Gil; Coralie Alonso; Joseph A Zasadzinski
Journal:  Biophys J       Date:  2005-05-27       Impact factor: 4.033

Review 6.  Toxic oxidant species and their impact on the pulmonary surfactant system.

Authors:  E Putman; L M van Golde; H P Haagsman
Journal:  Lung       Date:  1997       Impact factor: 2.584

7.  Calf Lung Surfactant Recovers Surface Functionality After Exposure to Aerosols Containing Polymeric Particles.

Authors:  Amir M Farnoud; Jennifer Fiegel
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-02-11       Impact factor: 2.849

8.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

9.  In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.

Authors:  B Lachmann; E P Eijking; K L So; D Gommers
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

10.  The effect of titanium dioxide nanoparticles on pulmonary surfactant function and ultrastructure.

Authors:  Carsten Schleh; Christian Mühlfeld; Karin Pulskamp; Andreas Schmiedl; Matthias Nassimi; Hans D Lauenstein; Armin Braun; Norbert Krug; Veit J Erpenbeck; Jens M Hohlfeld
Journal:  Respir Res       Date:  2009-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.